Live News Categoriesmarket

LABT.O (LABT.O) News

Follow LABT.O (LABT.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 1 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol LABT.O Asset market Sector Markets 90 days 1 Updated Sep 18, 2026, 12:17 PM UTC Open live news feed

L Lakewood — Amedex wins IRB approval for Phase 2a Nu — 3 diabetic foot ulcer trial Lakewood-Amedex won central IRB clearance for its Phase 2a Nu-3 trial in mildly infected diabetic foot ulcers. All participating sites also secured IRB sign-off, clearing the way to start patient enrollment. Disclaimer: NEWS | Sep 18, 2026, 12:17 PM UTC